Floatz logo

INTERFERON ALFA-2B

Colorectal Tumors

Roswell Park Cancer Instituteprotein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Colorectal Tumors cohort.

Asset / SponsorPhaseRating
Ad-Cea Vaccine
National Cancer Institute (NCI)
Phase 2CCC
Everolimus
The Queen Elizabeth Hospital
Phase 1/2CCC
Nelfinavir
Maastricht Radiation Oncology
Phase 1/2CCC
Avelumab
National Cancer Institute (NCI)
Phase 2CCC
Rintatolimod
Roswell Park Cancer Institute
Phase 1/2CC

Same molecule, other indications

INTERFERON ALFA-2B is also rated in:

melanomaDormant
BB
Indicative ·
68 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Stage IV Renal Cell CancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →